Introduction
============

Depression is more common in RA than in the general population \[[@ket169-B1]\] and has been associated with increased pain \[[@ket169-B2]\], fatigue \[[@ket169-B3]\], reduced health-related quality of life \[[@ket169-B4]\], increased levels of physical disability \[[@ket169-B5]\] and increased health care costs \[[@ket169-B6]\]. Depressed RA patients have poorer long-term outcomes, including increased pain \[[@ket169-B7]\], more comorbidities \[[@ket169-B8]\] and increased mortality levels \[[@ket169-B9]\]. Depression may therefore be a useful target for interventions aimed at improving subjective health and quality of life in RA patients. However, prevalence estimates for depression in RA range between 9.5% \[[@ket169-B10]\] and 41.5% \[[@ket169-B11]\], making it difficult to establish the likely impact of depression in this patient group.

There are various reasons why this variation in prevalence estimates may exist. First, the term depression is not clear-cut. Making sense of depressive symptoms in the context of chronic physical disease is challenging---it may be difficult to distinguish between patients with a depressive disorder, as opposed to those demonstrating a normal reaction to living with a chronic, debilitating condition. Further, a number of somatic symptoms of depression (e.g. fatigue, poor sleep and loss of appetite) might be expected to occur in RA as part of the disease process. To overcome this, researchers have adapted diagnostic thresholds to define caseness \[[@ket169-B12]\] or removed items that may be confounded by RA symptoms, for example, items assessing fatigue or sleep quality \[[@ket169-B13]\]. Such variations in definitions of depression may influence prevalence estimates.

Second, there are a multitude of methods available to detect depression. The gold standard method is psychiatric interview and diagnosis according to Diagnostic and Statistical Manual (DSM) \[[@ket169-B14]\] or International Classification of Diseases (ICD) \[[@ket169-B15]\] criteria. However, such interviews are time consuming and expensive and therefore often not ideal for examining patients in a busy hospital environment \[[@ket169-B16]\]. Alternatively, self-report screening questionnaires, such as the Patient Health Questionnaire (PHQ) \[[@ket169-B17]\] and the Hospital Anxiety and Depression Scale (HADS), may be used. These self-report tools are quick and easy to complete, meaning they are often preferred by researchers attempting to collect a large amount of data from a large sample; they are also cheaper to use than diagnostic interviews. Prevalence estimates according to screening tools are often based on predefined thresholds, which may result in overestimations of prevalence, as screening questionnaires tend to prioritize sensitivity over specificity \[[@ket169-B16]\].

Study quality may be a further explanation for the variance in prevalence estimates. Small studies lead to variable and imprecise prevalence estimates. Sampling strategies may influence prevalence estimates, with studies using convenience sampling or low participation rates giving unrepresentative samples that may be healthier than the target population \[[@ket169-B18]\]. Furthermore, the population studied can impact prevalence estimates; some studies may include patients with specific disease durations, or those using a particular type of medication, which may impact prevalence levels \[[@ket169-B19], [@ket169-B20]\].

There has only been one previous systematic review of depression in RA, which examined the strength of the association between depression and RA \[[@ket169-B21]\]. As yet no systematic review has provided pooled prevalence estimates of depression in RA. The present study aims to fill this gap. We aimed (i) to present a pooled prevalence level of depression in RA patients; (ii) to provide a summary of the methods used to define depression in RA and (iii) to explore the impact of study characteristics on prevalence estimates.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

The systematic review protocol and data extraction forms were designed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA; \[[@ket169-B22]\]) by F.M. and L.R. F.M. conducted a systematic search of Web of Science, CINAHL, PsycINFO, Medline, Embase and PubMed, from inception to October 2012. Sample search terms can be found in [supplementary Appendix S1](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online.

Inclusion and exclusion criteria
--------------------------------

Studies met the following inclusion criteria: (i) Cross-sectional design, baseline cross-sectional data from a longitudinal study or baseline cross-sectional data from a trial, before group allocation. (ii) Reported a prevalence level for depression using diagnostic criteria, a research diagnostic tool or a validated screening tool ([Table 1](#ket169-T1){ref-type="table"}). (iii) Reported prevalence level as the number of participants meeting predefined criteria for depression, or a percentage from which the number of participants meeting criteria for depression could be calculated. (iv) The sample size was ≥50. T[able]{.smallcaps} 1Overview of prevalence studies of mood in RA patientsStudy IDSampling method^a^Quality^b^Sample sizeMean age ([s.d.]{.smallcaps}), yearsSetting^c^Criteria for detection of depression (threshold)Women, %CountryPrevalence, %Abdel-Nasser 1998186039.7 (10.9)1DSM-III-R80.0Egypt23.3Alishiri 20081541146.8 (12)1HADS (9)87.3Iran23.4Azad 20080086NS1HADS (9)NSPakistan55.8Barlow 19991310256.31HADS (8/11)82.4UKHADS ≥ 8:28.4, HADS ≥ 11:14.7Bartlett 2003157757.55CESD (9)80.5USA31.2Chandarana 1987148656.01HADS (9)74.0Canada19.0Chaney 1996165852.0 (12.5)1IDD for DSM-IV81.0USA14.0Chang 20070250952.0NSHADS (8/11/15)73.0USAHADS ≥ 8:40.7, HADS ≥ 11:18.5, HADS ≥ 15:4.5Chow 2001009349.6 (12.3)1HADS (11)87.0Malaysia17.2Covic 20060013457.9 (12.2)1CESD (16)77.0Australia40.0Covic 2009009256.3 (13.7)1HADS (8/11) CESD (16/19) CESD 13 (9/13)62.0UKHADS ≥ 8:22.6, HADS ≥ 11:9.7, CESD ≥ 16:45.3, CESD ≥ 19:35.9, CESD-13 ≥ 9:26.6, CESD-13 ≥ 13:8.1Cunningham 20030114159.6 (10.3)NSCESD (12)100.0USA13.0Dirik 20100411748.5 (13.2)4HADS (8)84.6Turkey55.6El-Miedany 2002158041.9 (8.4)1ICD-1088.7Egypt66.3Escalante 20001623655.21CESD (16)62.0USA42.0Fifield 19921498851.0 (10.0)1CESD (16)78.0USA32.0Frank 19881513758.3 (9.6)5DIS for DSM-III24.1USAMDD: 17, dysthymia: 40.7Frank 1991157455.81IDD for DSM-IIINSUSADSM-III: 27, DSM-III-R: 16.2Goodenow 19901619450.71CESD (16)100.0USA22.7Hagglund 1989165256.5 (11.9)1BDI (10/19/30)61.5USABDI ≥ 10:35, BDI ≥ 19:23, BDI ≥ 30:20Hanly 2005125352.01HADS (11)84.9Canada0.04Hewlett 1995005058.01HADS (8/10)74.0UKHADS ≥ 8:20 HADS ≥ 10:00Hewlett 2002159360.0 (10.8)1HADS (11)64.5UK20.4Hider 20091715956.4 (12.2)1HADS (8)72.0UK47.5Ho 20111610053.7 (13.6)1HADS (11)75Singapore15.0Ichikawa 1995009253.4 (13.3)1SRS (40)82.6Japan48.9Iriarte 20001416452.0 (12.8)1SRS (48)74Spain38.0Isik 2007148252.3 (11.9)NSDSM-IV84.1Turkey41.5Jacobi 20010572559.0 (14.2)5CESD (17)71The Netherlands20.3Karasu 2002007152.84BDI (not stated)70.4Turkey33.8Karpouzas 201014193NSNSPHQ-9 (10)NSUSA36.0Kasle 20080114856.6 (12.3)1CESD (27)77USA7.43Katz 19941672660.41S-GDS (7)77USA14.0Kobayashi-Gutierrez 20091379NS1CESD (16)NSMexico26.6Krug 1997137758.2 (11.4)1BDI (10)22.0USA35.0Lindroth 1994167862.01HADS (10)83.3Sweden25.6Lok 20101920051.4 (10.5)1SCID for DSM-IV79.0Hong KongMajor depression: 9.5, depressive disorder: 1.5, dysthymic disorder: 3.5, adjustment disorder and depression: 0.5MacKinnon 19980414349.6 (11.2)1CESD (16)74.8Canada28.7Margaretten 20111546654.0 (14.0)1PHQ-9 (10)85.0USA37.0Massardo 20010275Median: 53.01CESD (16)93.3Chile47.0Mella 2010136251.1 (12.8)1HADS (7)83.9Brazil53.2Mikuls 2003159874.6 (3.8)2GDS-5 (2)100.0USA24.5Mo 20101597NS1HADS (11)NSUK2.9Murphy 19881580Median: 62.04PAS for DSM-III80.0UK12.5Murphy 19991662Median: 59.51HADS (10)83.9UK17.0Nas 20111542150.11HADS (7)82.9Turkey75.0Pastor-Oliver 19980222155.4 (12.4)5SRS (48)84.2Spain33.5Penninx 199616210NS2CESD (16)NSThe Netherlands41.4Piergiacomi 1989135051.4 (13.5)1CESD (19)74.0Italy42.0Pincus 19960416361.2 (13.7)1HADS (8/11)72.0UKHADS ≥ 8:23 HADS ≥ 11:15Pinheiro 20100250151.01HADS (11)NSBrazil20.6Plach 20030115659.0 (11)5CESD (15)100.0USA35.0Raspe 1987007549.0NSBDI-SF (8)79.0Germany22.0Revenson 19910310151.01CESD (16)82.0USA36.0Rivero-Carrera 20110011351.01CESD (16)89.4Venezuela29.0Scott 200702534NS1HADS (11)NSUK18.0Sharpe 2001165355.1 (14.1)1HADS (7)70.0Australia15.0Sinclair 20100212557.8 (15.4)3CESD (23)73.6USA16.0Smarr 200015426Median: 62.01CESD (10)57.0USA29.8Spicer 19981446160.8 (13.3)3GDS (5/10)81.0USAGDS ≥ 5:11 GDS ≥ 10:2Takeda 2000048556.0 (11.6)1SRS (40)100.0Japan56.5Taylor-Gjevre 20111214554.2 (15.7)1CESD (15)78.0Canada37.2Tomasevic-Todorovic 2011016049.9 (7.6)1BDI (16)88.3Serbia63.33Treharne 20051315456.3 (15.1)1HADS (10)73.0UK16.0Uguz 2009158349.9 (13.1)1SCID for DSM-IV89.2TurkeyMajor depression: 21.8, dysthymia: 13.3van Hoogmoed 20100422855.9 (10.8)1BDI-pc (4)63.0The Netherlands7.0Wilkins 2000009652.71CESD (16)87.1USA60.0Worral 20071261Median: 60.01HADS (11)77.0UK11.5Wright 19960314157.81CESD (16)45.0USA29.8Wright 19980349560.05CESD (16)59.6USA30.3Zamani 20100081NS1BDI (not stated)NSIran22.2Zaphiropoulos 1974125053.74BDI (15)72.0UK46.0[^1]

Studies were excluded if they: (i) used a selective sample (e.g. intervention trials after group allocation); (ii) used a paediatric sample; (iii) retrospectively reviewed medical records to establish depressive symptomatology.

For the meta-analysis, studies using a screening tool without stating the cut-off threshold used to detect depression were excluded. [Table 2](#ket169-T2){ref-type="table"} provides a full list of the eligible methods of detecting depression, alongside the numbers of articles utilizing each method and the number of participants assessed. T[able]{.smallcaps} 2Methods of detecting depression and summary of prevalence and heterogeneity findingsToolDefinition/thresholdNo. of studiesNo. of participantsPrevalence, % (95% CI)Heterogeneity *I*^2^, %Diagnostic criteria    DSMMajor depression448016.8 (10, 24)73.4Dysthymic disorder342018.7 (−2, 39)97.2Unspecified depression22806.4 (−4, 17)88.1Depressive disorder12001.5---Adjustment disorder and depression12000.5---    ICD-10Unspecified depression18066.3---Screening questionnaires Beck Depression Inventory (BDI)10212934.9 (27, 43)0.01515046.0---1616063.3---1915223.0---301522.0---    BDI-SF[^a^](#ket169-TF2){ref-type="table-fn"}817522.0---    BDI-pc^b^412287.0---    Centre for Epidemiological Studies Depression Scale (CESD)917731.2---10142629.8---12114113.0---15230136.2 (31, 42)0.01614333336.0 (32, 40)83.117172520.3---19214237.9 (30, 46)0.023112516.0---2711487.4---    CESD-13^c^919226.6---131928.1---    Geriatric Depression Scale (GDS)514612.0---10146111.0---    S-GDS^d^7172614.0---    GDS-5^e^219824.5---    Hospital Anxiety and Depression Scale (HADS)7353648.0 (9, 87)98.587119334.2 (25, 44)90.99358332.1 (14, 50)94.410434414.9 (4, 26)90.91112239814.8 (12, 18)74.01515094.5---    Inventory to Diagnose Depression (IDD)DSM-III17427.0---DSM-III-R17416.2---DSM-IV15814.0---    Patient Health Questionnaire (PHQ-9)10265938.8 (34, 43)19.8    Self-Rating Scale (SRS)40272652.6 (52, 60)1.84829835.3 (31, 40)0.0[^2]

Data extraction and quality assessment
--------------------------------------

F.M. conducted the primary data extraction. All articles were examined independently by a second reviewer (L.R.). Inter-rater disagreement was minimal, and any disagreements were resolved through discussion and reexamination of the article in consultation with M.H. When multiple publications spanned the years of longitudinal studies, baseline prevalence levels were reported. A 10-point quality assessment tool ([supplementary Appendix S2](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online) was devised to assess sampling method, sample size, participation rate, criteria used to determine depression and the eligibility criteria for participation in the studies. Articles were scored as follows: 0--3 = low quality; 4--6 = low to medium quality; 7--8 = medium to high quality; 9--10 = high quality.

Outcome measures
----------------

Outcomes were major depression, minor depression, depressive/mood/affective disorder, dysthymic disorder or adjustment disorder, defined by diagnostic interview or according to a defined threshold on a screening tool.

Statistical analyses
--------------------

Data were pooled according to diagnosis of depression or screening tool and threshold used to detect caseness. Heterogeneity was found to be moderately high between studies, and therefore random-effects meta-analyses with 95% CIs were conducted with STATA (version 10.0). Heterogeneity was assessed using *I*^2^, with thresholds of ≥25%, ≥50% and ≥75% indicating low, moderate and high heterogeneity, respectively \[[@ket169-B23]\].

Sensitivity analyses explored whether prevalence estimates were influenced by study design. Planned sensitivity analyses included the following: exclusion of studies with a participation rate ≤75%, or non-reported participation rate; exclusion of studies not stating a sampling strategy, or using a convenience/non-randomized sampling strategy; exclusion of studies that did not state eligibility criteria for inclusion in the study and exclusion of studies using subsets of patients (for example, a female-only sample or patients with limited disease duration). Subgroup analyses were planned by overall study quality, sample size, country of origin and publication year, if there was more than one study in the subgroup. Spearman's correlation analyses with adjusted *r*^2^ assessed the impact of study variables on prevalence estimates. Funnel plots were produced to explore the possibility of publication bias due to preferential publication of small studies reporting high prevalence estimates; Begg-Mazumdar and Egger's tests of publication bias were also performed.

Results
=======

Search results
--------------

The search yielded 28 328 relevant articles ([Fig. 1](#ket169-F1){ref-type="fig"}). After removal of duplicates, titles and then abstracts were screened for potential eligibility. All non-RA articles were removed, resulting in 806 potentially eligible studies. These were screened according to the inclusion and exclusion criteria for entry into the study, resulting in a total of 101 eligible studies. After taking into account multiple publications from the same sample, 72 articles were included in the review. F[ig]{.smallcaps}. 1Search results and study selection.

Included studies
----------------

[Table 1](#ket169-T1){ref-type="table"} presents the 72 papers included in the review (see [supplementary Appendix S3](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online). Seven studies used diagnostic criteria (DSM or ICD), and the remaining 66 used (one or more) screening tools to detect depression (PHQ-9, IDD, HADS, CESD, BDI, SDS or GDS), the most popular being the HADS and the CESD. The studies represented a total of 13 189 patients with RA; the median of mean ages was 53.7 years \[interquartile range (IQR) 51.0--56.5\], and the median percentage of females represented in the sample was 77.0% (IQR 70.4--82.9%). Sample sizes ranged from 50 to 988 participants (median = 96.0; IQR 75.0--159.0).

Quality assessment
------------------

[Table 1](#ket169-T1){ref-type="table"} presents the quality assessments for the 72 papers, according to the quality assessment tool ([supplementary Appendix S2](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online). The overall quality of the articles was poor with a median quality score of 3/10 (IQR 1--5). Eleven papers (15%) scored 0/10, and 82% of papers scored 5/10 or lower. No papers achieved the maximum score of 10; however, one received 9 out of 10 \[[@ket169-B10]\]. Specifically, 16.6% of studies had a sample size larger than 300, only 41.7% stated a participation rate and of these, only 40% had a participation rate ≥75%. Only 55.6% reported participant eligibility criteria for entry into the study.

Defining depression
-------------------

Depression was defined in 40 different ways ([Table 2](#ket169-T2){ref-type="table"}). The studies using diagnostic interviews reported three different subtypes of depression: major depressive disorder (MDD), minor depression (MD) and dysthymic disorder (DD), as well as combinations of disorders (depression with adjustment disorders or anxiety) and unspecified depression. Studies using screening questionnaires defined possible or probable caseness using multiple thresholds or detected any depression using one threshold. According to diagnostic criteria, MDD and DD were the most commonly diagnosed depressive subtypes. A full explanation of the differences between depressive diagnoses can be found in [supplementary Appendix S4](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online.

The most commonly used screening questionnaire was the HADS, with 30 studies using this screening tool. However, six different thresholds were presented in the articles, with the conventional cut-offs of 8 (probable depression) and 11 (definite depression) being the most commonly used. Twenty-five articles used the CESD; nine different cut-off points were presented, the most commonly used being 16. Eight papers used the BDI, with five different thresholds for depression.

Prevalence of depression
------------------------

Prevalence of depression alone (excluding combination disorders) ranged between 0.04% and 66.3% in individual studies ([Table 1](#ket169-T1){ref-type="table"}). [Table 2](#ket169-T2){ref-type="table"} presents the summary of meta-analyses and heterogeneity assessments. Meta-analytical pooled prevalence of MDD ([Fig. 2](#ket169-F2){ref-type="fig"}) according to the DSM diagnostic criteria was 16.8% (95% CI 10.0%, 24.0%), with moderate heterogeneity (*I*^2^ = 73.4%). Dysthymic disorder (according to DSM criteria) showed a pooled prevalence level of 18.7% (95% CI −2.0%, 39.0%), with high heterogeneity (*I*^2^ = 97.2%). F[ig]{.smallcaps}. 2Prevalence of MDD in RA.Pooled prevalence of MDD according to DSM criteria in RA patients by random effects meta-analysis.

Prevalence of depression according to the PHQ-9, with a threshold of 10 indicating moderate-severe depressive symptoms, was 38.8% (95% CI 34.0%, 43.0%), with low heterogeneity (*I*^2^ = 19.8%).

Analyses of screening questionnaires according to the threshold used to detect depression were conducted. As expected, higher thresholds yielded lower prevalence estimates. For example, the HADS shows an estimated prevalence of 34.2% when used with a threshold of 8, and a prevalence of 14.8% when used with a threshold of 11 ([Fig. 2](#ket169-F2){ref-type="fig"}).

Assessment of publication bias (see [supplementary Appendix S5](http://rheumatology.oxfordjournals.org/lookup/suppl/doi:10.1093/rheumatology/ket169/-/DC1), available at *Rheumatology* Online) indicated significant publication bias, according to the Egger's test, in studies reporting MDD according to DSM criteria \[Begg-Mazumdar: Kendall's *τ* = 1.36, *P* = 0.17, Egger: bias = 4.59 (95% CI 1.36%, 7.82%), *P* = 0.03\]. There was no significant evidence of publication bias in any other analyses.

Sensitivity and subgroup analyses
---------------------------------

[Table 3](#ket169-T3){ref-type="table"} shows prevalence estimates according to each sensitivity and subgroup analysis, in comparison with the primary analysis. The results of the sensitivity analyses indicated no particular trend or pattern according to the exclusion of studies with only abstracts available, the exclusion of studies with unreported participation rates or participation rates ≤75%, the removal of studies using convenience, non-randomized, or with unreported sampling strategies, or the exclusion of studies using subsets of patients. Exclusion of studies with no reported eligibility criteria tended to increase prevalence estimates, with the exception of the CESD (threshold 16). The subgroup analyses were conducted according to sample size, overall quality and publication year. The subgroup analyses for sample size and overall quality showed no clear patterns. However, more recent publications tended to yield higher prevalence estimates. T[able]{.smallcaps} 3Impact of study characteristics on prevalence estimates for depression in RA: sensitivity and subgroup analysesDepression definition (threshold)Major depression (DSM)Dysthymic disorder (DSM)HADS (7)HADS (8)HADS (9)HADS (10)HADS (11)CESD (16)Primary analysis16.8 (10, 24) *I*^2^ = 73.4% 4 studies 480 patients18.7 (−2, 39) *I*^2^ = 97.2% 3 studies 420 patients48.0 (9, 87) *I*^2^ = 98.5% 3 studies 536 patients34.2 (25, 44) *I*^2^ = 90.9% 7 studies 1193 patients32.1 (14, 50) *I*^2^ = 94.4% 3 studies 583 patients14.9 (4, 26) *I*^2^ = 90.9% 4 studies 344 patients14.8 (12, 18) *I*^2^ = 74.0% 12 studies 2398 patients36.0 (32, 40) *I*^2^ = 83.1% 14 studies 3333 patientsSensitivity analyses    Excluding studies at high risk of bias---7.8 (2, 17) *I*^2^ = 83.7% 2 studies 283 patients---35.2 (23, 47) *I*^2^ = 83.5% 2 studies, 611 patients22.4 (18.6, 26.1) *I*^2^ = 2.8% 2 studies 497 patients---16.4 (14, 18) *I*^2^ = 16.2% 9 studies 1752 patients32.9 (30, 38) *I*^2^ = 51.3% 8 studies 2145 patients    Excluding studies with only abstracts available------65.1 (44, 87) *I*^2^ = 90.8% 2 studies 483 patients33.0 (21, 45) *I*^2^ = 91.4% 6 studies 684 patients------13.8 (9, 18) *I*^2^ = 77.3% 7 studies 1137 patients35.4 (31, 40) *I*^2^ = 83.3% 13 studies 302 patients    Excluding studies with unreported PR or PR \<75%15.5 (2, 29) *I*^2^ = 82.2% 2 studies 260 patients------41.9 (22, 62) *I*^2^ = 95% 3 studies 440 patients---21.6 (14, 29) *I*^2^ = 23.1% 2 studies 140 patients14.7 (11, 19) *I*^2^ = 24.2% 4 studies 453 patients37.7 (29, 46) *I*^2^ = 77.6% 3 studies 589 patients    Excluding convenience non-randomized or unreported sampling methods16.8 (10, 24) *I*^2^ = 73.4% 4 studies 480 patients18.7 (2, 39) *I*^2^ = 97.2% 3 studies 420 patients48.0 (9, 87) *I*^2^ = 98.5% 3 studies 536 patients38.1 (19, 57) *I*^2^ = 90.2% 2 studies 262 patients---18.9 (14, 24) *I*^2^ = 25.7% 3 studies 294 patients12.2 (7, 17) *I*^2^ = 67% 6 studies 506 patients33.2 (26, 40) *I*^2^ = 85.8% 5 studies 1707 patients    Excluding studies with no reported eligibility criteria for participants16.8 (10, 24) *I*^2^ = 73.4% 4 studies 480 patients18.7 (2, 39) *I*^2^ = 97.2% 3 studies 420 patients48.0 (9, 87) *I*^2^ = 98.5% 3 studies 536 patients43.8 (29, 59) *I*^2^ = 89.6% 3 studies 379 patients39.2 (7, 71) *I*^2^ = 96.9% 2 studies 497 patients21.6 (14, 29) *I*^2^ = 23.1% 2 studies 140 patients14.9 (10, 20), *I*^2^ = 0% 2 studies 202 patients28.6 (25, 32) *I*^2^ = 28.5% 6 studies 1153 patients    Excluding studies using subsets of patients[^a^](#ket169-TF4){ref-type="table-fn"}16.8 (10, 24) *I*^2^ = 73.4% 4 studies 480 patients18.7 (2, 39) *I*^2^ = 97.2% 3 studies 420 patients---32.6 (21, 45) *I*^2^ = 92.6% 5 studies 931 patients---14.6 (−1, 30) *I*^2^ = 92.2% 3 studies 190 patients14.7 (12, 18) *I*^2^ = 76.3% 11 studies 2203 patients37.1 (33, 41) *I*^2^ = 80.7% 13 studies 2932 patientsSubgroup analyses Sample size50--14919.3 (15, 24) *I*^2^ = 0% 3 studies 280 patients26.6 (0.3, 53) *I*^2^ = 95.7% 2 studies 220 patients34.0 (3, 71) *I*^2^ = 95.6% 2 studies 115 patients30.0 (15, 46) *I*^2^ = 92.6% 4 studies 422 patients37.1 (0.6, 74) *I*^2^ = 96.7% 2 studies 172 patients14.6 (−1, 30) *I*^2^ = 92.2% 3 studies 190 patients12.0 (9, 16) *I*^2^ = 60.3% 8 studies 691 patients37.8 (31, 45) *I*^2^ = 81.9% 9 studies 974 patients150--399---------37.0 (24, 50) *I*^2^ = 92.6% 3 studies 832 patients---------35 (23, 48) *I*^2^ = 92.2% 3 studies 640 patients400+------------------19.0 (17, 21) *I*^2^ = 0% 3 studies 1544 patients31.7 (29, 34) *I*^2^ = 0% 2 studies 1483 patients Overall quality0--3 (low)---------28.6 (18, 39) *I*^2^ = 87.3% 4 studies 753 patients---8.9 (9, 23) *I*^2^ = 93.7% 2 studies 204 patients14.6 (12, 19) *I*^2^ = 81.4% 8 studies 1945 patients37.9 (31, 45) *I*^2^ = 83.2% 8 studies 1326 patients4--6 (medium)18.4 (13, 24) *I*^2^ = 0% 2 studies 220 patients26.6 (0.3, 53) *I*^2^ = 95.7% 2 studies 220 patients45.4 (−14, 104) *I*^2^ = 99.2% 2 studies 474 patients39.3 (8, 71) *I*^2^ = 96.9% 2 studies 280 patients22.4 (19, 26) *I*^2^ = 2.8% 2 studies 497 patients21.6 (12, 29) *I*^2^ = 23.1% 2 studies 140 patients14.7 (11, 19) *I*^2^ = 24.2% 4 studies 446 patients33.5 (27, 40) *I*^2^ = 85.7% 5 studies 1771 patients Publication year1990s------65.1 (44, 87) *I*^2^ = 90.8% 2 studies 483 patients24.2 (2, 29) *I*^2^ = 0% 3 studies 315 patients---14.6 (−1, 30) *I*^2^ = 92.2% 3 studies 190 patients15.1 (12, 19) *I*^2^ = 0% 2 studies 265 patients31.3 (28, 35) *I*^2^ = 69% 7 studies 2272 patients2000s---------37.3 (25, 49) *I*^2^ = 89.4% 3 studies 761 patients39.2 (7, 71) *I*^2^ = 96.9% 2 studies 497 patients---14.2 (10, 19) *I*^2^ = 81.2% 7 studies 1435 patients43.5 (35, 52) *I*^2^ = 79.3% 6 studies 712 patientspost-2010------------------15.7 (9, 22) *I*^2^ = 77.2% 3 studies 698 patients--- Country of originAmerica---------------------35.5 (29, 42) *I*^2^ = 88.7% 7 studies 2251 patientsUK---------28.6 (19, 39) *I*^2^ = 86.4% 5 studies 567 patients---11.5 (0.3, 23) *I*^2^ = 90.4% 3 studies 266 patients14.6 (11, 18) *I*^2^ = 47.9% 7 studies 1142 patients---Asia------------------16.0 (11, 21) *I*^2^ = 0% 2 studies 193 patients---[^3][^4]

Associated study variables
--------------------------

Spearman's correlation analyses with adjusted *r*^2^ were used to assess the associations between linear variables including participation rate, sample size, overall study quality, publication year, proportion of female participants, mean age of participants and mean duration of illness. [Table 4](#ket169-T4){ref-type="table"} shows the results of these analyses. T[able]{.smallcaps} 4Spearman\'s rank correlations between study characteristics and prevalence estimatesStudy characteristicNo. of studiesPrevalence estimate*ρP*Participation rate300.210.27Sample size72−0.070.53Overall quality72−0.0040.97Publication year720.110.36Female, %640.200.11Mean age60[\*](#ket169-TF5){ref-type="table-fn"}−0.30[\*](#ket169-TF5){ref-type="table-fn"}0.02[\*](#ket169-TF5){ref-type="table-fn"}Mean duration of disease360.020.90[^5]

A significant relationship was found between mean age and prevalence estimate; lower age was associated with increased depression prevalence (*r* = −0.3, *P* = 0.02). No other study characteristics showed a significant association with prevalence estimate.

Discussion
==========

Depression is highly prevalent in RA patients. Estimates varied according to the way in which depression was measured, but our pooled estimates from the small number of studies using gold standard clinical interviews suggest that major depression is present in 16.8% of RA patients. The larger number of studies using screening tools found significant depressive symptoms present in 38.8% using the PHQ-9 and between 14.8% and 48% using the HADS. These prevalence estimates are considerably higher than those observed in the general population \[[@ket169-B1]\] and are similar to, or higher than, those observed in patients with diabetes \[[@ket169-B24]\], Parkinson's disease \[[@ket169-B25]\] and cancer \[[@ket169-B26]\]. Although studies varied widely in terms of quality (and many were of poor quality), our sensitivity analyses indicate that prevalence estimates were reasonably stable. Apart from the measurement tool used to ascertain depression, study quality and study population had little impact on the estimates detected.

The RA patient population represents a largely female, older adult population \[[@ket169-B27]\]. It could be suggested that the inflated levels of depression found in this sample represent the increased risk of depression found in females and the elderly \[[@ket169-B28], [@ket169-B29]\], regardless of the presence of RA. However, as we found a significant negative association between age and depression prevalence estimate, it is more likely that our findings represent and increased risk of depression in RA patients in comparison with the general population.

A bewildering diversity of assessment measures were used to ascertain depression. This is similar to the situation in other physical diseases \[[@ket169-B30]\]. In this review, we did not include many studies that did not use validated measures of depression or questionnaires that assess a broader overlapping concept of psychological distress. Nevertheless we found that many studies used idiosyncratic cut-off scores on screening tools, meaning that the range of estimates for one such measure (the HADS) varied from 14.8% to 48%. Because there have not been validation studies to determine the best cut-point for such screening tools in this population, one clear recommendation is that investigators justify the use of idiosyncratic thresholds, and always report prevalence at conventional cut-points as well, to allow cross-study comparisons.

We used rigorous methods to conduct the review, with a sensitive search, and a reproducible, structured approach to data extraction and synthesis. We took a broadly inclusive approach to inclusion of studies, preferring to include less rigorous studies and explore the impact of study design in sensitivity analyses than to exclude such studies from the outset. It is possible that publication bias affected our results. We explored this using funnel plots and Egger's test where the assumption made was that small studies reporting low prevalence of depression would be less likely to be published than small studies reporting high prevalence. We only found evidence of potential publication bias in the studies that used diagnostic interviews. This is surprising since the efforts taken to conduct such studies are considerable and we would have anticipated these to be least likely to be affected by publication bias.

There are, however, additional important shortcomings in the evidence on prevalence of depression in RA that need to be addressed. The limited number of studies using structured clinical interview and determining depression according to DSM and ICD criteria is a concern. The high rates of depressive symptomatology detected through the screening tools could be due to the overlap between the somatic symptoms of depression and symptoms of RA. Symptoms frequently associated with depression (such as fatigue and reduced sleep quality) may be experienced by RA patients regardless of whether depressive symptoms are present or not. For example, 7 out of the 21 BDI items assess somatic symptoms, leading to concerns about the validity of this questionnaire in medical patients \[[@ket169-B31]\]. Similarly, a modified version of the CESD has been suggested for use with patients with RA, due to the symptom overlap \[[@ket169-B32]\]; however, only two articles in the current review used the modified versions available \[[@ket169-B33], [@ket169-B34]\].

A further consideration is the representativeness of the sample from which prevalence levels are estimates. Low socio-economic status (SES) patients are often under-represented in research samples \[[@ket169-B35]\]. This can be problematic, as low SES is associated with increased susceptibility to depression \[[@ket169-B36]\] and RA \[[@ket169-B37]\]. Many of the studies included in this review did not measure SES appropriately, with most studies using a single measure of education level or monthly income to indicate SES. This level of heterogeneity makes it difficult to establish the representativeness of the samples included with regard to SES. However, it is possible that a selection bias favouring high SES patients exists and the results of this systematic review may therefore underestimate the prevalence of depression.

The meaning of depression in the context of RA is not straightforward. Emotional responses to a physical illness characterized by pain and debility are understandable, and somatic symptoms of depression (e.g. loss of appetite and poor sleep) might be expected as part of RA. Therefore there is a need to ensure that measures of depression used in clinical practice are validated, both against a recognized criterion (e.g. the 'gold standard' clinical interviews) and also in terms of predictive validity (i.e. to determine the impact of depression on RA outcomes). Psychometric approaches utilizing longitudinal data may further be able to distinguish subtypes of depressive symptoms and thereby distinguish symptoms that are most likely to be core to the depressive syndrome.

Ultimately the key question is whether improved patient outcomes can be attained by recognizing and managing depression more effectively. There is growing evidence that incorporating a system of collaborative and stepped care of depression in patients with physical illness, which might include routine screening for depression with referral for highly structured manualized therapies depending on the outcome of screening, is effective treatment \[[@ket169-B38]\]. The high prevalence of depression in RA suggests that this would be a suitable patient group in which to test such strategies.

Rheumatology key messagesDepression is highly prevalent in RA patient groups.Increased depression prevalence in RA is significantly associated with low mean age.
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[^1]: NS: not stated; PAS: Psychiatric Assessment Schedule; SCID: Structured Clinical Interview for DSM; DIS: Diagnostic Interview Schedule. ^a^0: convenience/non-randomized, or undefined sampling strategy, 1: consecutive/randomized sampling strategy. ^b^Quality rated out of 10: 0--3: low quality; 4--6: medium quality; 7--8: medium-high quality; 9--10: high quality. ^c^1: outpatient, 2: database, 3: panel from longitudinal study, 4: inpatient/outpatient, 5: outpatient/community.

[^2]: ^a^BDI Short Form; ^b^BDI for Primary Care; ^c^13-item CES-D; ^d^Short GDS; ^e^5-item GDS.

[^3]: The first line in each set of data is percentage prevalence (95% CI).

[^4]: ^a^Reasons for exclusion: female only sample, limited disease durations examined; only patients using anti-tumour necrosis factor therapy treatment; only one ethnicity represented in sample.

[^5]: \*Significant at a *P* \< 0.05 level.
